LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02, amounting to USD 200.00 million in total. No changes in the number of authorized shares were recorded during the month.

The total number of issued shares stands at 3.99 billion. As of the end of February 2026, there were no treasury shares, and no increase or decrease in the issued shares during the month. The public float threshold remains at 25.00%, and the requirement has been confirmed as complied with.

A convertible bond with a principal amount of USD 180.00 million was also disclosed. The subscription price is HKD 4.88 per share, and up to 288.79 million new ordinary shares may be issued if fully converted. No new shares have been issued or transferred from treasury in connection with this instrument during the reporting period.

The company confirms, to the best knowledge and belief, that all necessary authorizations, regulatory requirements, and conditions related to the securities issuance have been fulfilled, including receipt of all funds due, submission of requisite filings, and compliance with all listing rules. The return was submitted by Director Ms. Zhu Yuan Yuan on 05 March 2026.